Stamp LK, et al. - This extension study including participants of a randomised controlled trial, entailed the assessment of long-term safety and efficacy of allopurinol dose escalation (DE) to achieve target serum urate (SU) in gout. It was documented that the majority of people with gout tolerated higher than creatinine clearance-based allopurinol dose and achieved and maintained target SU. In clinical practice, appropriateness of slow allopurinol DE was suggested, even in those with kidney impairment.